Characteristics and mechanism of action
The sole clinical representative of this group is drotrecogin alfa (activated), which is a recombinant analogue of activated protein C.
The anticoagulant effect is exerted through the proteolytic inactivation of blood coagulation cofactors — factor Va and factor VIIIa. As a result of this action, further generation of thrombin is blocked.
Additional pharmacological properties
In addition to its effect on blood coagulation, the substance exhibits other important properties:
- Fibrinolytic activity: achieved by reducing the concentration of plasminogen activator inhibitor type 1 (PAI-1), which stimulates fibrinolysis.
- Anti-inflammatory effect: the drug suppresses the release of TNF-alpha (tumor necrosis factor) from monocytes.
Clinical use and risks
The clinical indication for such agents is the treatment of septic shock. This therapeutic strategy is justified by the pathogenesis of severe sepsis, which concurrently involves systemic inflammation and pronounced hypercoagulation.
The primary adverse side effect associated with the use of the drug is hemorrhagic reactions.
Class and exam questions
Which drug represents the group of anticoagulants suppressing factors Va and VIIIa?
The sole representative discussed in the material is drotrecogin alfa (activated), a recombinant analogue of activated protein C.
What is the mechanism of the anticoagulant action of drotrecogin alfa?
The drug carries out proteolytic inactivation of blood coagulation cofactors — factor Va and factor VIIIa, leading to the inhibition of thrombin synthesis.
How is the fibrinolytic effect of the agent achieved?
The fibrinolytic effect is provided by lowering the level of plasminogen activator inhibitor type 1 (PAI-1).
Why are these anticoagulants used in septic shock?
The rationale is rooted in the pathogenesis of sepsis, which is simultaneously accompanied by systemic inflammation and hypercoagulation—processes targeted by the drug.
What else to study on this topic
- Structure and functions of the recombinant analogue of activated protein C
- Molecular mechanisms of inactivation of cofactors Va and VIIIa
- Interaction between the coagulation and plasminogen systems (effect on PAI-1)
- The role of TNF-alpha and monocytes in the anti-inflammatory response of the drug
- Pathogenetic features of septic shock as an indication for therapy
- Prevention and management of hemorrhagic complications
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Anticoagulants inhibiting factors Va and VIIIa" and 5,304 other pages on the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Drugs affecting hemostasis and thrombosis"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.